甲胎蛋白与肝癌免疫的研究进展  

Advanced progress in alpha-fetoprotein and hepatocarcinoma immunity

作　　者：赵倩[1] 王小平[1] 胥冰[1] 蔺焕萍[1] 张克佩[1] 

机构地区：[1]陕西中医药大学分子病理学研究室,咸阳712046

出　　处：《生物学杂志》2016年第2期95-99,共5页Journal of Biology

基　　金：国家自然科学基金项目(81172135;81310108008);陕西教育厅科研计划项目(07JK233;10JK484;14JS025)

摘　　要：肝癌是常见的消化道恶性肿瘤,目前没有较好的治疗措施。甲胎蛋白在肝癌细胞中高表达,除了用于肝癌诊断外,其作为肿瘤相关抗原已成为肝癌免疫治疗的靶点。虽然甲胎蛋白免疫原性较弱,并通过抑制树突状细胞,自然杀伤细胞以及T淋巴细胞功能促进肝癌细胞免疫逃逸,但其在肝癌免疫治疗中的作用也日益受到重视,通过体外修饰增强其免疫原性促进免疫应答,从而提高杀伤肝癌细胞免疫效应。甲胎蛋白在肝癌发生、发展及免疫中的作用为研究其在肝癌中的免疫治疗奠定了良好的基础。Hepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. Excepting for its diagnosis in liver cancer,AFP has become the target for liver cancer immunotherapy. Although AFP＇ s immunogenicity is weak and can promote the immune escapes by inhibiting the function of dendritic cells,natural killer cells and T lymphocytes,AFP has drawn more attention in liver cancer immunotherapy. By in vitro modification,the immunogenicity and immune effect of AFP could be enhanced. The important role of AFP in development,progression and immunity of liver cancer can lay a better foundation in hepatocarcinoma immunotherapy.

关 键 词：甲胎蛋白 肝癌免疫 多肽疫苗 热休克蛋白 

分 类 号：R735.7[医药卫生—肿瘤]